Log in

NYSE:PFE - Pfizer Stock Price, Forecast & News

$36.51
-0.42 (-1.14 %)
(As of 02/16/2020 01:33 PM ET)
Add
Today's Range
$36.42
Now: $36.51
$37.04
50-Day Range
$36.93
MA: $38.98
$40.71
52-Week Range
$33.97
Now: $36.51
$44.56
Volume19.93 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio12.72
Dividend YieldN/A
BetaN/A
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
CUSIP71708110
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees92,400
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.


Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Monday, December 16th. Stockholders of record on Friday, January 31st will be paid a dividend of $0.38 per share on Friday, March 6th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.16%. The ex-dividend date of this dividend is Thursday, January 30th. This is a positive change from Pfizer's previous quarterly dividend of $0.36. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer announced that its Board of Directors has initiated a stock repurchase program on Friday, December 14th 2018, which allows the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 3.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company's management believes its shares are undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) issued its quarterly earnings results on Tuesday, January, 28th. The biopharmaceutical company reported $0.55 EPS for the quarter, missing analysts' consensus estimates of $0.57 by $0.02. The biopharmaceutical company had revenue of $12.69 billion for the quarter, compared to the consensus estimate of $12.73 billion. The company's quarterly revenue was down 9.2% on a year-over-year basis. During the same quarter last year, the business posted $0.64 EPS. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY20 earnings guidance on Tuesday, January, 28th. The company provided EPS guidance of $2.82-$2.92 for the period, compared to the Thomson Reuters consensus estimate of $2.72. The company issued revenue guidance of $48.5-$50.5 billion, compared to the consensus revenue estimate of $47.44 billion.

What price target have analysts set for PFE?

12 analysts have issued 1 year target prices for Pfizer's stock. Their forecasts range from $36.00 to $53.00. On average, they anticipate Pfizer's share price to reach $42.03 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. According to Zacks Investment Research, "The Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away. Pfizer expects continued strong growth of key brands like Ibrance and Eliquis and biosimilars to drive sales in the second half. Pfizer is also strengthening its pipeline and hopes to launch new innovative medicines in the next five years, which can drive long-term growth. However, currency headwinds, weak sales in the sterile injectables portfolio, pricing pressure and some recent negative product developments for Prevnar and Xeljanz, are top-line headwinds. Shares have underperformed the industry this year so far. " (10/1/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (2/19/2019)

Has Pfizer been receiving favorable news coverage?

Press coverage about PFE stock has trended neutral this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pfizer earned a news impact score of 0.2 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Pfizer.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Verizon Communications (VZ), Johnson & Johnson (JNJ), Intel (INTC), General Electric (GE), AbbVie (ABBV), Exxon Mobil (XOM), Bank of America (BAC) and Walt Disney (DIS).

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Exec. Chairman (Age 65)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
  • Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (5.27%), Bank of New York Mellon Corp (1.08%), Massachusetts Financial Services Co. MA (0.94%), Charles Schwab Investment Management Inc. (0.72%), LSV Asset Management (0.54%) and Franklin Resources Inc. (0.52%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, PGGM Investments, California Public Employees Retirement System, LSV Asset Management, CI Investments Inc., PNC Financial Services Group Inc., KBC Group NV and State of Tennessee Treasury Department. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Marshall Wace North America L.P., Sanders Capital LLC, Bank of New York Mellon Corp, FIL Ltd, Sound Shore Management Inc. CT, Marshall Wace LLP and Stifel Financial Corp. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $36.51.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  1,342 (Vote Outperform)
Underperform Votes:  958 (Vote Underperform)
Total Votes:  2,300
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel